Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With coming down as fast as we did over a short period of time, I would have thought that the shorts went way up. Buy NO, This price just doesn't make sense to me ..... it also doesn't make any cents to me.
Does anyone know if the short interest has gone way up since we been dropping? Thank You
To me it is a very perplexing situation because, like everyone (or most), I sit here and say ... Gee, I could have sold at $3.50 and now bought back even more shares at $2.30.
But the reason I don't sell at $3.50 is NOT because I don't realize that it may go beck down, But because I wouldn't want to sell at $3.50 and THEN have the news come out that jumps it to $10.
So what the hell do I do except more of the same?
I don't know, sad, just sad. who's next, james allison.
I'm a bit confused. Is Ann Leen gone? Is she still with MRKR? Is she doing something else at MRKR? I don't think it would be a good sign if she has moved on from MRKR.
As we were just recently at a high of $3.77, did I read somewhere that Peter just put in 2 1/2 million of his own money to buy 1 million shares at $2.50? Was that in an article somewhere. That would almost make us think that he knows something and believes in the company.
OK, I am going to mention another company, NOT because I like it, but as an example of the MRKR crazy market cap.
AND, over the last few years, I could have showed you this EXACT same senerio dozens and dozens of times.
OK, today IMNM Immunome has a market cap of 450 million, 3 times that of MRKR ... and I've seen this situation with market caps all the way up to 2 Billion.
WHAT DOES IMNM have in their pipeline?
NOTHING AT ALL.
WHAT DOES IMNM have in Phase 2 trials?
NOTHING AT ALL.
WHAT DOES IMNM have in Phase 1 trials?
NOTHING AT ALL.
WHAT DOES IMNM have in Pre-Clinical trials?
NOTHING AT ALL.
They have TWO products in "DISCOVERY", they make a B.S. Covid release ... and they are worth THREE TIMES what MRKR is when MRKR has patients living 3 1/2 years now.
So, OK, someone PLEASE explain the logic of this to me.
Oh stay above $3 already so we can establish the next higher base.
$2.99 , that's funny. Hope we continue slow and steady climb next week without any big proit taking or MM messing around.
HOLD THREE DOLLARS.
Happy it's up, a bit worried that it's Friday, you know the MM's are going to try to close under $3. We need a whale.
yep, most of my bios are red, I want to hold $3.
We really need to hold $3 today and Friday.
I'll go backwards and start with price. I'm with you, I think WHEN the good news is out my $7.15 avg should be at $20/$25.
On other cancers, as I said before, I'm not a Doctor or scientist, BUT what always intriged me was two things, #1 was the GREAT advantage of NO Cytokine release storm and #2, is that they kept saying and talking about "Epitope spreading". I read that (with my limited understanding) that OK, they gave their "5" antigen cocktail to fight a specific cancer but then the epirope spreading created a dozen more or so other cancer fighting antigens (or whatever) to appear that also fight cancers.
So I just guessed that all these other from the epitope spreading would have to be effective against other cancers.
Without a press release, we know MRKR is not going to do the up 100% or 200% in aftermarket/premarket we see happen almost EVERY morning (examples CGIX BPTH BHTG this morning). We just need to steady along, if we can be at $3.75 by end of friday, I'm fine.
Then next week try to hold $4.25 by end of week.
We WILL get the giant blast up WHEN the PR/news gets everyones attention, and then Baker Brothers and others will jump back in and maybe we can get to the $20 to $30 range .... I HOPE.
I'm hoping for what you talked about, the stair steps up with higher highs and higher lows. My break even is $7.19 so I got a ways to go before any profits.
Holding above $3, I'll take it.
OK, it's going to pull back some. Can we hold $2.75 and be around that on Friday? Hope so. Well actually I hope it's $10 by Friday, but ...
That, and a build up of a few things. Building in Texas completed, trial data "leaked" last week in a report, some reddit and robinhoods jumping in, etc.
Still WAY undervalued long term right here.
I remember back during merger times, when people were throwing around a 1 billion post merger market cap. I said then that after decades on microbiotech investing and looking at all comparables, MRKR should be a 250 to 350 million market cap and I thought the billion number was way pushing it then.
I STILL believe they were worth about the 250 million back then, so now after more trials and data and time and a new giant building in Texas, with ANY good news it should be a times 2 to a times 4, so YES, our 150 mil market cap right now is still nuts. We should be double that right now, BEFORE any further good news ...... whick I DO BELIEVE will come.
Our market cap is now 150 million. STILL A JOKE ... should be 10 times that ... at least.
Step by step. Step #1, hold these gains (most of them anyway). Step #2, GO HIGHER.
I would Hope. But after our experience over the last two years????????????
OK. Check out this article:
https://seekingalpha.com/article/4404194-hey-redditors-redirect-your-attention-to-marker
This has to be Marker. All the authors are from Baylor.
Spyridoula Vasileiou, PhD1; Premal D. Lulla, MD1; Ifigeneia Tzannou, MD1; Ayumi Watanabe, BSc1; Manik Kuvalekar, MSc1; Wendy L. Callejas, BSc1; Mrinalini Bilgi, BSc1; Tao Wang, PhD1; Mengfen J. Wu, BSc1; Rammurti Kamble, MD1; Carlos A. Ramos, MD1; Rayne H. Rouce, MD1; Zihua Zeng, MD1; Adrian P. Gee, PhD1; Bambi J. Grilley, RPh1; Juan F. Vera, MD1; Catherine M. Bollard, MD1; Malcolm K. Brenner, MD, PhD1; Helen E. Heslop, MD1; Cliona M. Rooney, PhD1; Ann M. Leen, PhD1; and George Carrum, MD1
1Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX
I see Juan Vera, Helen Heslop, Ann Leen.
The 5 TAA targets are what Marker is using.
Feb. 3, 2021 @ $1.86 - GO TEAM
Well, I kept asking on this board, WHY are they building, WHY??? For WHAT product, they MUST have an answer.
It was just hard for me to believe that they would do a massive build out ... without ALREADY having a reason.
So along with you, I am hoping they are getting paid the big bucks for a reason.
We shall see.
Well, it's good that our new manufacturing facility in Texas is complete and ready to go.
Now we just need 2 things, #1 a product to manufacture, and #2 the reason to manufacture that product.
So we wait on the trials and we wait on the FDA after that.
All dressed up in Texas and no place to go.
Oops, wrong stock, was thinking about ZNGA.
Thank You for the info.
Thank You, Let's just hope for something big around May 2021 for Pancreatic because July of 2022 seems like a LONG time away.
I'm kind of with you. The back door/merge in may not have been the best way. It DOES have it's advantages if you don't want to deal with a year of SEC paperwork and hoops to jump through. That is why the SPAC's have been so popular recently.
But the traditional roadshow and IPO may have the best way to go long term (in hindsight being that most of our early investors dumped us).
YEP, that's why I play biotechs. It's where you get those overnight 500%, 1000% jumps up. Over the decades, I've seen this more times than I can remember. Been lucky enough to have been in a few. It may show my age but I remember buying Pharmacyclics (bought by AbbVie), and Vertex and Mirati (used to be MethylGene) when they were still small companies.
Sometimes it just takes a while, longer than expected. All 3 of them took Many Years.
Hopefully it is us in MRKR one day soon.
I think I remember complaining more than a year ago that I just looked at about 3 dozen small biotechs that ALL had way less of a pipeline than MRKR, ALL were either in "PRE-clincal" or JUST started Phase 1, and ALL had a market cap of 5 times to 20 times what MRKR was at.
It was crazy to me then and it is still crazy to me now.
I just hope our day will come and we will shoot up 1000% or 2000% on some great data.
Question for Phantom ... if he sees it.
For AML, what exactly is the milestone news we are waiting for? Phase 2 final data?
For Pancreatic, what exactly is the milestone news we are waiting for? Phase 1 final data?
And WHEN approximately, roughly, a good estimation, should we be expecting those two?
Not when are they going to compile the data, when are they going to Release the data to the public?
Thank You and for everybody losing their @$$ like me, we only got 2 choices, sell at a big loss, or hold out and hope.
Once again Thank You for the article which included Novartis. In a strange way the fact that FDA gave Novartis a hard time makes me feel better .... in a, it helps disperse the "big pharma and FDA colluding" theory. As in, colluding to help the big guys by holding back small guys medicine.
Definitely has been Frustrating. I'd love to know WHY the FDA went after MRKR for this unneeded additional information? Do they ever do the same thing to Big Pharma and ask for something ridiculous info to slow down a trial?
Covid vaccine is URGENT ... done in 12 months.
What? AML or Pancreatic cancer is not URGENT so we can ask for nonsense and slow down the trial.
And THANKS for the straight info, I thought current management was in place when reagent was decided.
P.S. I'm getting a bit tired of eating turkey and stuffing. Hope 2021 is a much better year on many fronts.
A lot on the subject of blame, and wasted opportunities, and wasted cash.
Listen, it all sucked since we were at $7 and hoping it went to $10.
Covid hurt MRKR and most other biotechs and their trials, but the blame would go to China or wet markets or the lab that created it or etc.
The reagent fiasco, Peter or SOMEBODY should have MADE SURE the company that was supplying the reagent had the PROPER PAPERWORK. That WAS wasted time and money for no reason.
The TPIV efforts that didn't work out wasn't an intentional waste of time/money. It was just what small biotechs do. They go with their idea, spend time and money on it, and then it either does or does not work out.
In hindsight, maybe should have been ditched earlier to focus on AML and Pancreatic.
The only thing we can expect is basically nothing happening until we get good data from a trial or until they tell us EXACTLY what the new facility is for and WHEN will it start to produce revenue.
I still own my stupid amount of shares and already lost every penny in MRKR call options, but no one held a gun to my head and made me buy any of it, so I guess part of the BLAME is mine.
YAWN!